Autor segons l'article: Olloquequi J; Ettcheto M; Cano A; Sanchez-López E; Carrasco M; Espinosa T; Beas-Zarate C; Gudiño-Cabrera G; Ureña-Guerrero ME; Verdaguer E; Folch J; Auladell C; Camins A
Departament: Bioquímica i Biotecnologia
Autor/s de la URV: Folch Lopez, Jaume
Paraules clau: Synapses Novel therapies Nonsteroidal antiinflammatory drugs Neuroinflammation Dementia Clinical studies synaptic loss synapses receptor novel therapies neuropathologic assessment neuroinflammation mild cognitive impairment mast-cells hypothesis clinical studies brain amyloid-beta oligomers
Resum: The increases in population ageing and growth are leading to a boosting in the number of people living with dementia, Alzheimer's disease (AD) being the most common cause. In spite of decades of intensive research, no cure for AD has been found yet. However, some treatments that may change disease progression and help control symptoms have been proposed. Beyond the classical hypotheses of AD etiopathogenesis, i.e., amyloid beta peptide (Aβ) accumulation and tau hyperphosphorylation, a trend in attributing a key role to other molecular mechanisms is prompting the study of different therapeutic targets. Hence, drugs designed to modulate inflammation, insulin resistance, synapses, neurogenesis, cardiovascular factors and dysbiosis are shaping a new horizon in AD treatment. Within this frame, an increase in the number of candidate drugs for disease modification treatments is expected, as well as a focus on potential combinatory multidrug strategies.The present review summarizes the latest advances in drugs targeting Aβ and tau as major contributors to AD pathophysiology. In addition, it introduces the most important drugs in clinical studies targeting alternative mechanisms thought to be involved in AD's neurodegenerative process.
Àrees temàtiques: Química Medicine (miscellaneous) Medicine (all) Medicina iii Medicina ii Medicina i Interdisciplinar Immunology and microbiology (miscellaneous) Immunology and microbiology (all) General immunology and microbiology General biochemistry,genetics and molecular biology Farmacia Enfermagem Educação física Economia Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Ciência de alimentos Cell biology Biotecnología Biodiversidade Biochemistry, genetics and molecular biology (miscellaneous) Biochemistry, genetics and molecular biology (all) Biochemistry & molecular biology
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
Adreça de correu electrònic de l'autor: jaume.folch@urv.cat
Identificador de l'autor: 0000-0002-5051-8858
Data d'alta del registre: 2024-09-07
Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
Enllaç font original: https://www.imrpress.com/journal/FBL/27/5/10.31083/j.fbl2705146
URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
Referència a l'article segons font original: Frontiers In Bioscience-Landmark. 27 (5): 146-
Referència de l'ítem segons les normes APA: Olloquequi J; Ettcheto M; Cano A; Sanchez-López E; Carrasco M; Espinosa T; Beas-Zarate C; Gudiño-Cabrera G; Ureña-Guerrero ME; Verdaguer E; Folch J; A (2022). Impact of New Drugs for Therapeutic Intervention in Alzheimer's Disease. Frontiers In Bioscience-Landmark, 27(5), 146-. DOI: 10.31083/j.fbl2705146
DOI de l'article: 10.31083/j.fbl2705146
Entitat: Universitat Rovira i Virgili
Any de publicació de la revista: 2022
Tipus de publicació: Journal Publications